China-based Henan Celnovte Biotechnology Co., Ltd, a tumor in vitro diagnostic reagents (IVDs) and instruments maker, reportedly raised RMB 100 million (USD 14.15 million) via another financing round. Investors included Puhua Capital, Henan Hi-Tech Venture Capital, Zhengzhou High Tech Industry Investment Fund, and Zhong Yuan Lian Chuang Capital.
Company Background and Achievements
Founded in 2010, Celnovte Bio boasts 443 Category 1 medical device approvals and 56 CE-IVD certificates, with products covering immunohistochemistry, molecular pathology, and tissue staining pathology. The company’s products have entered into multiple Class 3A hospitals in China, including Henan Cancer Hospital, Ruijin Hospital, West China Hospital, and Xiangya Hospital.-Fineline Info & Tech
